-
WHO grants emergency usage listing for Covaxin
Covaxin has demonstrated 77.8% effectiveness against symptomatic COVID-19 and 65.2% protection against the new Delta variant
-
Covaxin for children likely to be rolled out in phases: Report
According to sero-surveys, India has about 400 million children, of whom nearly 60% or 240 million have already developed antibodies
-
Covaxin gets emergency use approval for kids aged 2-18 years
For final clearance, the recommendations have been sent to the Drugs Controller General of India (DCGI).
-
Indian students can travel to Australia as Covishield get approval down under
Australia had imposed very strict travel restrictions on people travelling in and out of the country
-
Phase 2 and 3 trials of paediatric Covaxin completed
For ramping up production of Covaxin, Bharat Biotech has collaborated with Indian Immunologiclas and Hester Biosciences
-
Covid vaccine export to be resumed from October: Union health minister Mansukh Mandaviya
The government's Vaccine Maitri programme to help the global supply of vaccines aims will increase the rate of production in October- December quarter
-
COVAX cuts delivery target by 25% due to supply constraints
As per the latest supply forecast, 1.1 billion doses are expected to become available for delivery between September and the end of 2021
-
India administers 1.25 crore Covid vaccines daily: PM Modi
Modi also appreciated the tireless efforts of Covid warriors, including doctors, paramedical staff, Asha and anganwadi workers, and teachers
-
Bharat Biotech ramps up production of Covaxin with new Gujarat plant
The new facility at Ankleshwar has a manufacturing capacity of more than 1 crore doses per month.
-
Bharat Biotech’s new plant releases first commercial batch of Covaxin
The manufacturer had announced in May that it would produce an additional 200 million doses of Covaxin at its subsidiary's Ankleshwar-based facility.
